pioglitazone has been researched along with Parkinson Disease, Secondary in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonato, JM | 1 |
| Bassani, TB | 1 |
| Milani, H | 1 |
| Vital, MABF | 1 |
| de Oliveira, RMW | 1 |
| Ulusoy, GK | 1 |
| Celik, T | 1 |
| Kayir, H | 1 |
| Gürsoy, M | 1 |
| Isik, AT | 1 |
| Uzbay, TI | 1 |
2 other studies available for pioglitazone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne | 2018 |
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Mot | 2011 |